CLDX
Celldex Therapeutics Inc
38.20$
-1.9%
vs. previous close
Closing price · As of: Sep 18, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +36.1% | +13.6% | -17.7% | -50.6% | -21.1% | +91.8% | +88.5% | -20.7% | +32.0% | +70.2% | -26.4% | |
| – | +43.9% | -33.7% | -26.0% | -31.6% | -32.7% | +196.6% | +107.7% | -22.7% | +35.9% | +73.1% | -28.4% | |
| – | +157.3% | -41.1% | -5.1% | -39.7% | -53.8% | +290.3% | -10.7% | -24.8% | +18.3% | -18.6% | +1.8% | |
| – | +44.2% | -34.5% | -26.5% | -32.6% | -31.7% | +202.9% | +110.0% | -25.3% | +38.3% | +72.0% | -28.5% | |
| – | +127.2% | +83.9% | +5.4% | +68.2% | -61.6% | +48.3% | -90.5% | +101.7% | +1,204.9% | -84.5% | +187.9% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +8.8% | +15.1% | -21.4% | -41.1% | -34.0% | +80.2% | -10.2% | +18.8% | – | – | – | |
| – | +0.0% | +914.8% | +0.0% | -100.0% | – | – | – | – | – | – | – | |
| – | -4.6% | +291.9% | -17.1% | -25.1% | -3.8% | -37.0% | -11.4% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | +30.6% | +148.4% | -32.8% | -59.9% | -9.0% | -8.4% | -4.9% | +5.4% | +37.4% | +24.4% | +23.1% | |
| – | +23.5% | +16.5% | -21.3% | -54.6% | -7.6% | +22.0% | +16.3% | +12.6% | +67.2% | +26.9% | +29.1% | |
| – | +70.4% | +9.2% | +36.1% | -31.1% | -57.0% | -31.7% | +31.6% | -17.2% | +11.7% | -10.0% | +6.9% | |
| – | -42.1% | +15.5% | -1.4% | -37.7% | +9.8% | -10.7% | +17.2% | +172.0% | +4.6% | -6.6% | -63.9% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +37.1% | -8.5% | -10.9% | -47.5% | -24.2% | +122.7% | +100.4% | -22.2% | +31.6% | +74.1% | -29.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +8.6% | +4.6% | +26.6% | +21.8% | +38.9% | +104.3% | +44.6% | +9.4% | +3.3% | +32.9% | +3.3% |
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.